Company: CRVO
Filing Date: 2025-05-12
Form Type: 424B5
Source: 0001437749-25-016167
Chunk: 17

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 424B5
Chunk 17
---
49 |
| Historical net tangible book value per share as of March 31, 2025                         |     | $ | 3.98 |     |   |      |
| Increase in net tangible book value per share attributable to the offering                |     | $ | 1.65 |     |   |      |
| As adjusted net tangible book value per share after giving effect to this offering        |     |   |      |     | $ | 5.63 |
| Dilution in net tangible book value per share to investors participating in this offering |     |   |      |     | $ | 2.86 |

The table above assumes for illustrative purposes that an aggregate of 5,889,281 shares of common stock are sold during the term of the Sales Agreement with Leerink Partners at a price of $8.49per share, the last reported sale price of our common stock on The NASDAQ Capital Market on May 9, 2024, for aggregate gross proceeds of approximately $50,000,000. The shares subject to the Sales Agreement with Leerink Partners are being sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $8.49per share shown in the table above, assuming all of our shares of common stock in the aggregate amount of approximately $50,000,000 during the term of the Sales Agreement with Leerink Partners is sold at that price, would increase our adjusted net tangible book value per share after the offering to $5.88 per share and would increase the dilution in net tangible book value per share to new investors in this offering to $3.61 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $8.49per share shown in the table above, assuming all of our shares of common stock in the aggregate amount of approximately $50,000,000 during the term of the Sales Agreement with Leerink Partners is sold at that price, would increase our adjusted net tangible book value per share after the offering to $5.34 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $2.15 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only. The